{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-25-000042","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.477090+00:00","generated_at":"2026-05-16T23:55:05.407852+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch","bullets":["Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.","Submitted NDA for low-dose estrogen weekly patch; advancing pipeline.","Acquired Aculys Pharma, gaining rights to Pitolisant (Japan) and Spydia (Japan & Asia-Pacific).","Year-to-date capital return >$920M, including $500M in share repurchases.","CEO cites strong execution and strategic review for sustainable growth in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-25-000042","json":"https://secwatch.observer/filing/0001792044-25-000042.json","markdown":"https://secwatch.observer/filing/0001792044-25-000042.md","text":"https://secwatch.observer/filing/0001792044-25-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/0001792044-25-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/vtrs-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:55:05.407852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}